Elcelyx Therapeutics reports positive Phase IIb study results of Metformin DR to treat type 2 diabetes

Elcelyx Therapeutics has reported that its Phase 2b dose-ranging study met the primary endpoint of indicating a statistically significant reduction in HbA1c at 16 weeks with Metformin Delayed Release (Metformin DR) compared with placebo in subjects w …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news